<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03852771</url>
  </required_header>
  <id_info>
    <org_study_id>CL-00383</org_study_id>
    <nct_id>NCT03852771</nct_id>
  </id_info>
  <brief_title>REST Study (CompRESsion Therapy for RLS)</brief_title>
  <acronym>REST</acronym>
  <official_title>CompRESsion Therapy for Restless Leg Syndrome: An Evaluation of Cirvo™ for the Treatment of Restless Leg Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radial Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radial Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study in patients with restless leg syndrome (RLS) will evaluate the use of Cirvo™
      therapy for the treatment of this disorder when applied to both legs.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company closure
  </why_stopped>
  <start_date type="Actual">March 12, 2019</start_date>
  <completion_date type="Actual">January 31, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in disease severity between the Baseline study visit and the 56-day visit, as assessed by the International Restless Leg Syndrome Study Group Severity Scale (IRLSS).</measure>
    <time_frame>56 days</time_frame>
    <description>Assessment of change in IRLSS scores from Baseline study visit to 56 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in disease severity between the Baseline study visit and the 56-day visit, as assessed by the Clinical Global Impression (CGI-I) rating scale.</measure>
    <time_frame>56 days</time_frame>
    <description>Change in disease severity as assessed by CGI-I scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sleep quality between the Baseline study visit and the 56-day visit, as assessed by the Medical Outcomes Study (MOS) sleep scale.</measure>
    <time_frame>56 days</time_frame>
    <description>Change in sleep quality as assessed by MOS sleep scale from Baseline to 56 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in disease severity between the Baseline study visit and after the last usage of the each parameter set trialed in Period 1 (nominally days 7, 14, 21, and 28), as assessed by the IRLSS.</measure>
    <time_frame>28 days</time_frame>
    <description>Assessment of IRLSS score after each week of programmed therapy for first 4 weeks of therapy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Therapy related adverse events</measure>
    <time_frame>56days</time_frame>
    <description>Assessment of adverse events</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive the intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cirvo(TM) therapy</intervention_name>
    <description>The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression to the lower leg.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female over the age of 18.

          2. Diagnosis of Restless Leg Syndrome (RLS) per the Hopkins-Hening Diagnostic
             Questionnaire

          3. International RLS Study Group (IRLSS) Score ≥15.

          4. RLS symptoms occurring on at least 5 nights each week, with symptoms stable for at
             least 3 months.

        Exclusion Criteria:

          1. Known or suspected deep vein thrombosis.

          2. Pregnancy

          3. Prior use with home intermittent pneumatic compression (IPC) device

          4. Currently using any other device to treat RLS

          5. Active skin infections in the affected leg

          6. Vein ligation or skin graft of the leg within past 12 months

          7. Mental or physical limitations that would prevent the subject from reliably completing
             study questionnaires.

          8. Physical impairments that would prevent the use of the CirvoTM device.

          9. Use of any medications typically used to treat RLS, where dose has not been stable for
             at least 2 months.

         10. If previously on medication to treat RLS, patient must have been weened under medical
             supervision and off medication for at least 14 days at time of enrollment

         11. History of pulmonary vascular disease (PVD)

         12. History of pulmonary edema

         13. History of decompensated congestive heart failure (CHF)

         14. Open surgery or major trauma to the legs within the last six months

         15. History of lower limb malignancy, primary or secondary

         16. Acute symptomatic lower extremity thrombophlebitis

         17. Any chronic back pain or lower extremity pain

         18. Other sleep problems that are felt to be currently affecting the quality of sleep

         19. Calf geometry on which Cirvo™ device does not appropriately fit

         20. Known sensitivity to any of the materials used in the Cirvo™ device

         21. Currently participating or plans to participate in in any other investigational
             clinical evaluation during the 56 day study period that may, in the opinion of the
             investigator, affect RLS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>California Center for Sleep Disorders</name>
      <address>
        <city>Alameda</city>
        <state>California</state>
        <zip>94501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

